Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C: a sleeping giant?

M J Alter1

  • 1Division of Viral and Rickettsial Diseases, Centers for Disease Control, Atlanta, Georgia 30333.

The American Journal of Medicine
|September 16, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.

Tropical medicine & international health : TM & IH·2006
Same author

Hepatitis B vaccination rate of homeless children in Baltimore.

Journal of pediatric gastroenterology and nutrition·2005
Same author

The epidemiology of acute and chronic hepatitis C.

Clinics in liver disease·2004
Same author

Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV.

Transfusion·2004
Same author

Protecting future generations through immunization against hepatitis B.

Annals of internal medicine·2001
Same author

Interpreting hepatitis B serologies.

Seminars in dialysis·2001
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Non-A, non-B hepatitis, now known as hepatitis C, is often acquired outside of blood transfusions. Antibody to hepatitis C virus (anti-HCV) indicates infection but may be delayed, highlighting the need for better detection methods.

Area of Science:

  • Hepatology
  • Virology
  • Epidemiology

Background:

  • Non-A, non-B hepatitis constitutes a significant portion (20-40%) of acute viral hepatitis cases in the U.S.
  • While historically linked to transfusions, non-A, non-B hepatitis is now more commonly identified outside transfusion settings.
  • Surveillance data reveals diverse transmission routes, including parenteral drug use (46%) and sexual/household exposure (10%).

Purpose of the Study:

  • To analyze the epidemiology of non-A, non-B hepatitis in the U.S.
  • To investigate the role of antibody to hepatitis C virus (anti-HCV) as an indicator of infection and infectivity.
  • To assess the prevalence of anti-HCV across different risk groups.

Main Methods:

  • Analysis of 1988 Centers for Disease Control surveillance data for non-A, non-B hepatitis cases.

Related Experiment Videos

  • Review of serologic studies on anti-HCV prevalence in various populations.
  • Correlation of anti-HCV status with infection source and clinical presentation.

    • Main Results:

    • Parenteral drug use and no known source were the most frequent risk factors (46% and 40%, respectively).
    • Antibody to hepatitis C virus (anti-HCV) is prevalent across most non-A, non-B hepatitis cases, regardless of infection source.
    • High anti-HCV rates (50-80%) were observed in parenteral drug users and hemophiliacs; lower rates in sexually active individuals and healthcare workers.
    • Anti-HCV presence in acute/chronic hepatitis C suggests infectivity, but its meaning in asymptomatic individuals requires further investigation.

    Conclusions:

    • Non-A, non-B hepatitis (hepatitis C) has multiple transmission routes, with parenteral drug use being a major factor.
    • Anti-HCV is a common marker for hepatitis C infection, though its appearance can be delayed (6-9 months).
    • Further research using more sensitive and specific markers is necessary to determine infectivity in anti-HCV positive individuals without a hepatitis history.